Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06557967 · ClinicalTrials.gov registry record
Study on Prevalence and Impact of Brain Metastases on Survival in Lung Cancer by Line of Treatment
A clinical trial of Non-Small Cell Lung Cancer and Lung Cancer, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- 22,517
- Enrollment target
- 1
- Study location
NCT06557967 is a study of Non-Small Cell Lung Cancer and Lung Cancer that has completed, run by Daiichi Sankyo. The registered enrollment target is 22,517 participants, above the 609-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (3597% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06557967, a study of Non-Small Cell Lung Cancer and Lung Cancer, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- 22,517 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will use real-world data to assess prevalence of brain metastases in metastatic non-small cell lung cancer (mNSCLC) patients and its impact on associated clinical outcomes.
Conditions Studied
Interventions
- OTHER No drug
Study Locations (1)
Massachusetts
- ConcertAI Database - Cambridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22,517 participants |
| Start Date | 2024-03-01 |
| Est. Completion | 2024-09-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06557967
The ClinicalTrials.gov registry entry for NCT06557967 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 22,517 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 609-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (3597% higher). The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which No drug is the first listed.
NCT06557967 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06557967 about?
NCT06557967 is a clinical study titled "Study on Prevalence and Impact of Brain Metastases on Survival in Lung Cancer by Line of Treatment". This study will use real-world data to assess prevalence of brain metastases in metastatic non-small cell lung cancer (mNSCLC) patients and its impact on associated clinical outcomes.
What is the current status of trial NCT06557967?
This trial is currently completed. The enrollment target is 22,517 participants. The study started on 2024-03-01. Estimated completion is 2024-09-30.
What conditions does trial NCT06557967 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Lung Cancer, Metastatic Cancer, Brain and Central Nervous System Cancer.
What interventions are being tested in trial NCT06557967?
The interventions under investigation include: No drug (OTHER).
Who is sponsoring clinical trial NCT06557967?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06557967 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.